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Introduction: Emtricitabine/rilpivirine/tenofovir (EVP) is a fixed-dose combination of antiretrovirals (ARV) approved by the
European Medicines Agency in November 2011 and introduced in Italy in February 2013. It is a once-a-day single tablet and is
licensed in Europe for use only in ARV-naı¨ve patients with a viral load (VL) 5100,000 copies/mL.
Objective: To identify factors that may be associated with the use of EVP as first-line regimen in HIV-infected individuals starting
cART from ARV-naı¨ve in Italy.
Methods: Clinical sites in ICONA Foundation Study in which ]1 person had started EVP were selected for this analysis. From
these we included all patients who started an EVP-based cART regimen as well as those starting other cART regimens after the
date of introduction of EVP at the site (after February 2013 in any case) and with a VL 5100,000 copies/mL from ARV-naı¨ve.
Characteristics at the time of starting cART were compared using chi-square test and unadjusted and adjusted logistic regression
analysis. Factors investigated included: gender, mode of HIV transmission, time from HIV diagnosis, CD4 count, nation of birth,
AIDS, HCV-status, age, CD8 count, VL, diabetes, smoking, total and HDL cholesterol, eGFR, blood glucose, level of education and
employment and site location. Factors showing unadjusted associations with a p-value of 10% or smaller, were retained in the
multivariable model.
Results: We identified 183 patients starting EVP and 173 starting the control regimen from 23 sites. The number of patients
starting EVP included at each site ranged from 1 to 12 and the number of those starting the control regimen was similar. The
most frequently used drugs in the concurrent group were: TDF (75%), FTC (74%), DRV (39%), ATV/r (26%), LPV/r (9%), EFV (13%)
and RAL (14%). In univariable analysis, there were differences in median CD4 count (390 cells/mm3 in EVP versus 348 in controls,
p0.002), time from HIV diagnosis to starting cART (11 versus 3 months, p0.001) and prevalence of students (6% versus 3%,
p0.07). No differences were observed for all other factors examined. The table shows estimates of the odds ratios (OR) for
factors included in the multivariable model.
Conclusions: CD4 count was higher in EVP-treated patients compared to controls. Guidelines suggest avoiding initiation of EVP in
presence of high VL, possibly explaining this residual difference in CD4. There was also a tendency to prescribe EVP to people
with perceived lower adherence or hesitant to start or perhaps with a slow progressing disease.
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Table 1. Odds ratios of starting Eviplera from fitting a logistic regression model
Odds ratios of starting eviplera
Characteristic
Unadjusted OR (95%
CI)
p-
value Adjusted OR (95% CI)
p-
value
CD4 count, cells/mmc (per 100 cells higher) 1.15 (1.03, 1.28) 0.014 1.17 (1.04, 1.32) 0.008
Time from HIV diagnosis to date of starting cART(per year
longer)
1.11 (1.03, 1.18) 0.004 1.10 (1.03, 1.18) 0.008
Employment, n (%)
Unemployed 1.00 1.00
Employed 1.69 (0.80, 3.55) 0.166 1.78 (0.79, 4.01) 0.162
Self-Employed 1.20 (0.50, 2.84) 0.686 1.25 (0.50, 3.14) 0.640
Occasional 1.71 (0.48, 6.11) 0.408 2.18 (0.58, 8.27) 0.251
Student 3.23 (0.93, 11.19) 0.065 3.49 (0.93, 13.08) 0.64
Retired/Invalid/Housewife 1.05 (0.28, 3.93) 0.945 0.65 (0.15, 2.71) 0.551
Other/unknown 1.72 (0.80, 3.68) 0.165 1.85 (0.79, 4.31) 0.155
Abstracts of the HIV Drug Therapy Glasgow Congress 2014
Cozzi-Lepri A et al. Journal of the International AIDS Society 2014, 17(Suppl 3):19775
http://www.jiasociety.org/index.php/jias/article/view/19775 | http://dx.doi.org/10.7448/IAS.17.4.19775
2
